The search for drugs that can kill replicating and nonreplicating Mycobacterium tuberculosis faces practical bottlenecks. Measurement of CFU and discrimination of bacteriostatic from bactericidal activity are costly in compounds, supplies, labor, and time. Testing compounds against M. tuberculosis under conditions that prevent the replication of M. tuberculosis often involves a second phase of the test in which conditions are altered to permit the replication of bacteria that survived the first phase. False-positive determinations of activity against nonreplicating M. tuberculosis may arise from carryover of compounds from the nonreplicating stage of the assay that act in the replicating stage. We mitigate these problems by carrying out a 96-well microplate liquid MIC assay and then transferring an aliquot of each well to a second set of plates in which each well contains agar supplemented with activated charcoal. After 7 to 10 days—about 2 weeks sooner than required to count CFU—fluorometry reveals whether M. tuberculosis bacilli in each well have replicated extensively enough to reduce a resazurin dye added for the final hour. This charcoal agar resazurin assay (CARA) distinguishes between bacterial biomasses in any two wells that differ by 2 to 3 log10 CFU. The CARA thus serves as a pretest and semiquantitative surrogate for longer, more laborious, and expensive CFU-based assays, helps distinguish bactericidal from bacteriostatic activity, and identifies compounds that are active under replicating conditions, nonreplicating conditions, or both. Results for 14 antimycobacterial compounds, including tuberculosis (TB) drugs, revealed that PA-824 (pretomanid) and TMC207 (bedaquiline) are largely bacteriostatic.
Rising antimicrobial
resistance challenges our ability to combat
bacterial infections. The problem is acute for tuberculosis (TB),
the leading cause of death from infection before COVID-19. Here, we
developed a framework for multiple pharmaceutical companies to share
proprietary information and compounds with multiple laboratories in
the academic and government sectors for a broad examination of the
ability of β-lactams to kill
Mycobacterium tuberculosis
(Mtb). In the TB Drug Accelerator (TBDA), a consortium organized
by the Bill & Melinda Gates Foundation, individual pharmaceutical
companies collaborate with academic screening laboratories. We developed
a higher order consortium within the TBDA in which four pharmaceutical
companies (GlaxoSmithKline, Sanofi, MSD, and Lilly) collectively collaborated
with screeners at Weill Cornell Medicine, the Infectious Disease Research
Institute (IDRI), and the National Institute of Allergy and Infectious
Diseases (NIAID), pharmacologists at Rutgers University, and medicinal
chemists at the University of North Carolina to screen ∼8900
β-lactams, predominantly cephalosporins, and characterize active
compounds. In a striking contrast to historical expectation, 18% of
β-lactams screened were active against Mtb, many without a β-lactamase
inhibitor. One potent cephaloporin was active in Mtb-infected mice.
The steps outlined here can serve as a blueprint for multiparty, intra-
and intersector collaboration in the development of anti-infective
agents.
As part of a program to explore the chemistry of β-lactams and their derivatives, we prepared a focused set of benzazetidine, indoline, and indole heterocycles, as well as flexible unconstrained variations of the four-membered heterocyclic compounds. These analogues mimic the threedimensional shape of cephalosporins but are not prone to covalent binding via ring opening. Although these analogues were inactive against the ESKAPE pathogens and Mtb, they represent unique and underexplored chemotypes for future biological screening.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.